System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Argiris Symeonidis is an expert in Hematology at General University Hospital of Patras (Greece). As of October 2026, ScienceLeadR ranks Argiris Symeonidis in the top 1% of experts worldwide for Lymphoproliferative Disorders. Argiris Symeonidis has authored 362 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 5 of them ongoing. SLR score: 1,479 (community average: 125). How the SLR is computed.

LeadR Profile

Argiris Symeonidis General University Hospital of Patras Greece
1 479 ScienceLeadR Reputation 1479

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Biochemistry - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026
Source: PubMed

University of Patras

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 362

Citations

Citations: 9 928 1st author: 33 Last author: 30 Unique author: 2

Main journals

Blood 116
Leuk Res 34
Hemasphere 12
Ann Hematol 11
Br J Haematol 11

Best Journals

N Engl J Med 7
J Clin Oncol 3
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Integrating paroxysmal nocturnal hemoglobinuria (PNH) into mainstream hematological curriculum training.
PMID 42836124 — hemoglobinuria, curriculum		Hemasphere20260
Integrating Gaucher disease (GD) into mainstream hematological curriculum training.
PMID 42824561 — curriculum, gaucher disease		Hemasphere20260
The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes.
PMID 42529759 — myelodysplastic syndromes, serum, predictive value of tests, erythropoietin, diagnosis, prognosis		EJHaem20260
RNA and Mitochondrial Reprogramming Associated with Azacytidine Treatment in Higher-Risk Myelodysplastic Syndromes: A Pilot Study.
PMID 42512367 — pilot projects, genes, pilots, myelodysplastic syndromes, adenosine, azacitidine, therapeutics, rna		Cancers (Basel)20260
Dapagliflozin in Patients with homozygous β-Thalassemia and Albuminuria.
PMID 42360912 — hematology, albuminuria, kidney, thalassemia, matrix metalloproteinases, therapeutics		Acta Haematol20261

Clinical Studies 27

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 21
N/A 3
Phase 2 3

By status:

Completed 15
Active not recruiting 7
Terminated 2
Unknown 2
Recruiting 1

By type:

Interventional 24
Observational 3

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 26

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to investigate the efficacy safety and pharmacokinetics of oral rilzabrutinib compared with placebo in participants 18 years of age and older with warm autoimmune hemolytic anemia
2024-517972-39-00 — safety, anemia, anemia, hemolytic, anemia, hemolytic, autoimmune, pharmacokinetics		Phase 3Recruiting2025
A clinical study that compares a treatment with Iberdomide Daratumumab and Dexamethasone against a treatment with Daratumumab Bortezomib and Dexamethasone in patients with a non responsive or progressive blood cancer called Multiple Myeloma
2024-510800-35-00 — blood, dexamethasone, neoplasms, bortezomib, multiple myeloma, therapeutics		Phase 3Active not recruiting2022
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE FL 2)
2023-506906-38-00 — lymphoma, follicular, safety, lymphoma, maintenance, drug-related side effects and adverse reactions, rituximab, lenalidomide, therapeutics, epcoritamab		Phase 3Active not recruiting2024
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR 2)
NCT05552976 — dexamethasone, multiple myeloma, calcium, calcium dobesilate		Phase 3Active not recruiting2023
Open label Study Comparing Iberdomide Daratumumab and Dexamethasone (IberDd) Versus Daratumumab Bortezomib and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997 — dexamethasone, bortezomib, multiple myeloma		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS